A chimeric antigen receptor (CAR) that binds to CEACAM6, an epitope or fragment thereof, or a variant thereof.

The present invention relates to variable domain of a camelid heavy-chain antibodies directed to amyloid β and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid β deposits.

The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (1ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.

This invention generally pertains to antibodies and antigen-binding antibody Fragments, preferably humanized, chimeric, and human antibodies and antigen-binding antibody fragments. compositions containing such antibodies and antigen-binding antibody fragments or cells, e.g., immune cells such as T, Treg, or NK cells which express same, wherein such antibodies and antigen-binding antibody Fragments specifically bind to mGluR5. The invention also relates to therapeutic and diagnostic uses for the antibodies, antigen-binding antibody fragments, and compositions thereof.

The present disclosure is directed to single domain antibodies that bind to α-synuclein and the use of these antibodies for the treatment and diagnosis of α-synucleinopathies The present disclosure is also directed to polynucleotides encoding the α-synuclein single domain antibodies, therapeutic vectors comprising these polynucleotides and methods of administering these therapeutic vectors for the treatment of α-synucleinopathies.

The present invention, in some embodiments thereof, is directed to an antigen-binding polypeptide having increased binding affinity to prostate specific membrane antigen (PSMA). In some embodiments, the present invention is further directed to the use of the antigen-binding polypeptide in the diagnosis and treatment of diseases associated with elevated expression of PSMA, such as prostate cancer.

The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.

The present disclosure provides, inter alia, nanobodies targeting a Ca.sub.Vβ auxiliary subunit and compositions thereof. Methods for blocking a High-Voltage Activated Calcium Channel (HVACC) using such compositions, methods for selectively targeting a population of cells in a subject, and methods for treating or ameliorating the effects of a disease in a subject are also provided.

The present disclosure provides an anti-immune-checkpoint nanobody that specifically binds to a programmed cell death ligand 1. The present disclosure also provides the nucleic acid sequence of the anti-immune-checkpoint nanobody, use of the anti-immune-checkpoint nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of PD-L1.

Provided is a nanometer antibody for human CD7 molecule and an encoding DNA sequence thereof. The nanometer antibody can be efficiently expressed in Escherichia coli, and can be used for preparing an agent for the detection of CD7 molecule and targeted therapy.